Project leader – Nicolò Riggi
 |
|
Division of Experimental Pathology
University Institute of Pathology
The Riggi Laboratory
Rue du Bugnon 25
1005 Lausanne Switzerland
E-Mail: Nicolo.Riggi@unil.ch
Phone: +41 21 314 71 11
|
|
Publications
|
2014 / 10.1016/j.ccell.2014.10.004
Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvà ML, Rossetti NE, Boonseng WE, Oksuz O, Cook EB, Formey A, Patel A, Gymrek M, Thapar V, Deshpande V, Ting DT, Hornicek FJ, Nielsen GP, Stamenkovic I, Aryee MJ, Bernstein BE, Rivera MN. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014 Nov 10;26(5):668-81
|
» PubMed |
2014 / 10.1158/0008-5472.CAN-14-1106
Cornaz-Buros S, Riggi N, DeVito C, Sarre A, Letovanec I, Provero P, Stamenkovic I. Targeting cancer stem-like cells as an approach to defeating cellular heterogeneity in Ewing sarcoma. Cancer Res. 2014 Nov 15;74(22):6610-22
|
» PubMed |
2013 / 10.1126/science.1230184
Suvà ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013 Mar 29;339(6127):1567-70
|
» PubMed |
2012 / 10.1016/j.ccr.2012.04.023
De Vito C, Riggi N, Cornaz S, Suvà ML, Baumer K, Provero P, Stamenkovic I. A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell. 2012 Jun 12;21(6):807-21
|
» PubMed |
2012 / 10.1101/gad.188292.112
Janiszewska M, Suvà ML, Riggi N, Houtkooper RH, Auwerx J, Clément-Schatlo V, Radovanovic I, Rheinbay E, Provero P, Stamenkovic I. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012 Sep 1;26(17):1926-44
|
» PubMed |
2011 / 10.1586/era.10.235
Riggi N, Suvà ML, Stamenkovic I. The cancer stem cell paradigm in Ewing's sarcoma: what can we learn about these rare cells from a rare tumor?. Expert Rev Anticancer Ther. 2011 Feb;11(2):143-5
|
» PubMed |
2011 / 10.1371/journal.pone.0023592
DeVito C, Riggi N, Suvà ML, Janiszewska M, Horlbeck J, Baumer K, Provero P, Stamenkovic I. Let-7a is a direct EWS-FLI-1 target implicated in Ewing’s sarcoma development. PLoSONE, 2011, 6:e23592
|
» PubMed |
2010 / 10.1101/gad.1899710
Riggi N, Suvà ML, De Vito C, Provero P, Stehle JC, Baumer K, Cironi L, Janiszewska M, Petricevic T, Suvà D, Tercier S, Joseph JM, Guillou L, Stamenkovic I. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 2010, 24:916-932
|
» PubMed |
2009 / 10.1158/0008-5472.CAN-09-1622
Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, Marquez VE, Clément V, Stamenkovic I. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009, 69:2911-2918
|
» PubMed |
2009 / 10.1158/0008-5472.CAN-08-2242
Suvà ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suvà D, Clément V, Provero P, Cironi L, Osterheld MC, Guillou L, Stamenkovic I. Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res. 2009, 69:1776-1781
|
» PubMed |
|
|